Akt inhibitor NTQ1062

An orally bioavailable inhibitor of the serine/threonine protein kinase Akt (protein kinase B), with potential antineoplastic activity. Upon oral administration, Akt inhibitor NTQ1062 targets, competitively binds to and inhibits the activity of Akt, which may result in the inhibition of the PI3K/Akt signaling pathway, thereby leading to the inhibition of cell proliferation and the induction of apoptosis in tumor cells. Activation of the PI3K/Akt signaling pathway is frequently associated with tumorigenesis and dysregulated PI3K/Akt signaling may contribute to tumor resistance to a variety of antineoplastic agents.